ArticleCureus2025
Myocardial Infarction in a Patient With Homozygous Plasminogen Activator Inhibitor-1 (PAI-1) 4G/4G Mutation: A Case Report.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Non-ST-elevation acute coronary syndrome (NSTE-ACS) resulting from genetic thrombophilias such as plasminogen activator inhibitor-1 (PAI-1) polymorphisms is extremely uncommon. We report the case of a 47-year-old male with no significant past medical history, aside from marijuana use, who presented with chest pain and elevated troponin levels. Coronary angiography demonstrated a thrombotic 100% occlusion of the left circumflex artery. A hypercoagulability workup revealed a homozygous 4G/4G PAI-1 gene polymorphism, consistent with an increased thrombotic predisposition, with marijuana use serving as a possible trigger. The patient was treated with aspirin, clopidogrel, and apixaban. This case illustrates a rare association between myocardial infarction and the PAI-1 4G/4G polymorphism and underscores the importance of considering thrombophilia testing in young patients with ACS who lack conventional cardiovascular risk factors.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.